Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Weber Shares Insight on Future of Immunotherapy in Melanoma

January 26th 2018

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

January 25th 2018

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Dr. Kluger on Systemic Management of Melanoma With Brain Metastases

January 25th 2018

Harriet Kluger, MD, professor of medicine, associate cancer center director for education and training, deputy section chief, Medical Oncology, Yale Cancer Center, discusses the progression of treatment for patients with melanoma who have brain metastases.

Ipilimumab Approved in Europe for Pediatric Melanoma

January 23rd 2018

Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

January 17th 2018

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Dr. Kudchadkar on Immunotherapy in Merkel Cell Carcinoma

January 10th 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Dr. Landi Discusses the Importance of Screening in Melanoma

January 9th 2018

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the importance of screening in melanoma.

Adjuvant Pembrolizumab Improves RFS in Melanoma

January 9th 2018

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Dr. Carvajal Discusses the Biology of Extracutaneous Melanoma

January 4th 2018

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

January 2nd 2018

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

December 22nd 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF+ Melanoma

December 22nd 2017

The FDA has granted a priority review to a supplemental new drug application for the use of dabrafenib combined with trametinib as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21st 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

FDA Approves Adjuvant Nivolumab for Melanoma

December 21st 2017

The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.

Dr. Schadendorf Discusses Sequencing Agents in Melanoma

December 21st 2017

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Immunotherapy Resistance Remains a Puzzle

December 15th 2017

Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.

Dr. Landi on the Association Between Genetic Variance and Melanoma Risk

December 14th 2017

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

Positive Topline Results Announced for Cemiplimab in Advanced CSCC

December 14th 2017

Results from EMPOWER-CSCC 1 showed that cemiplimab (REGN2810) induced an overall response rate of 46.3% in patients with advanced cutaneous squamous cell carcinoma.

Standard Adjuvant Therapy for Melanoma Within Reach

December 12th 2017

Michael B. Atkins, MD, discusses hotly debated adjuvant treatment options for patients with melanoma, and the potential for neoadjuvant therapy.

Combination Therapies Push Melanoma Field Forward

December 12th 2017

Michael A. Postow, MD, discusses the evolution of combination therapies for patients with melanoma.